Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Healthcare technology company Philips announced that it is investing more than $150 million in U.S. manufacturing and ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Wall Street braced for results from retail giants as rising concerns over inflation cloud the path to an interest rate cut.

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q2 CY2025, with ...

The global monoclonal antibody therapeutics market is set to witness a growth rate of ~12% in the next 5 years. Rising ...

Insulin Market to exceed US$ 31.5 Bn by 2035, expanding at 4.1% CAGR, driven by rising diabetes prevalence and growing access to advanced ...

The company is shifting some production from China and Mexico in a move that could soften the impact of tariffs.